ADT + darolutamide extends overall survival in men with nmCRPC

According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Enzalutamide extends OS compared to an standard antiandrogen in ENZAMET trial, but …

The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Long-term follow-up data from LATITUDE trial

Long-term follow-up data from the LATITUDE trial have now been published by Fizazi et al. in Lancet Oncology. … READ MORE …

Agent Orange and prostate cancer-specific survival on ADT

A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …

Is time to biochemical failure a good surrogate endpoint for overall survival?

For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …

Race and survival of men after docetaxel-based treatment for mCRPC

A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …

Survival of men with metastatic, castration-resistant prostate cancer

There has been regular discussion here and elsewhere about the degree to which new forms of therapy have impacted patient survival since the original approval of docetaxel for treatment of metastatic, castration-resistant  prostate cancer (mCRPC). … READ MORE …

MFS as an endpoint in clinical trials

Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of metastasis-free survival (MFS) as the study endpoint in clinical trials. … READ MORE …

MFS as a new endpoint in prostate cancer drug development

An article by staff at the U.S. Food and Drug Administration (FDA) in this week’s New England Journal of Medicine (NEJM) addresses the use of metastasis-free survival (MFS) as the primary endpoint in the trial that led to approval of apalutamide (Erleada) earlier this year. … READ MORE …

Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …

Escalated radiation dose doesn’t improve 8-year overall survival in intermediate-risk men (but does it matter?)

Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …

Initial local treatment and long-term survival of men with advanced prostate cancer

We have previously had no really accurate data on a very important question: Does local treatment of men initially diagnosed with advanced prostate cancer impact their long-term survival and mortality rates? … READ MORE …

Low PSA levels on ADT do correlate to longer survival times

For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”)  have significant predictive impact on long-term survival. … READ MORE …

Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

A Phase III clinical trial of high-intensity exercise in the management of advanced prostate cancer

According to a news release just issued by Queen’s University, Belfast, a group of  150 researchers around the world is coming together to expand enrollment and access to the Australian INTERVAL trial into a global trial to test whether serious exercise should be prescribed as part of the treatment for men with advanced prostate cancer. … READ MORE …